Literature DB >> 3261296

Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa.

B Ando1, T Wiedmer, K K Hamilton, P J Sims.   

Abstract

The functional and conformational activation of cell surface glycoproteins IIb-IIIa (GPIIb-IIIa) was probed in platelets stimulated to secrete by complement proteins C5b-9. Gel-filtered human platelets exposed to the purified human C5b-9 proteins exhibited non-lytic secretory release of both alpha- and dense granule storage pools with only a small increase in total binding of 125I-fibrinogen (less than 3000 molecules/cell) to the cell surface. By contrast to ADP- or thrombin-activated platelets, increased 125I-fibrinogen bound to C5b-9 platelets was not inhibited by Arg-Gly-Asp-containing peptides, suggesting that the high affinity membrane receptor for fibrinogen is not expressed under these conditions. C5b-9-stimulated platelets also failed to bind 125I-von Willebrand factor (less than 1 ng/10(8) platelets), confirming that the adhesive protein receptor function of cell surface GPIIb-IIIa is not expressed in these cells. Although specific binding of 125I-fibrinogen or 125I-von Willebrand factor did not significantly increase after C5b-9 assembly, these proteins elicited de novo expression of the GPIIb-IIIa activation-associated epitope recognized by monoclonal antibody PAC-1, and binding of this antibody to C5b-9 platelets was fully competed by Arg-Gly-Asp-containing peptides. These data suggest that the metabolic events which trigger granule secretion after C5b-9 insertion into the plasma membrane cause cell surface GPIIb-IIIa to be expressed in an activation-associated but functionally incompetent conformation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261296

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

Review 2.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

3.  Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin.

Authors:  B F Le Bonniec; C T Esmon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

4.  Complement proteins C5b-9 induce transbilayer migration of membrane phospholipids.

Authors:  B W Van der Meer; R D Fugate; P J Sims
Journal:  Biophys J       Date:  1989-11       Impact factor: 4.033

Review 5.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 6.  Pentraxins, anti-pentraxin antibodies, and atherosclerosis.

Authors:  N Bassi; S Zampieri; A Ghirardello; M Tonon; M Zen; F Cozzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

7.  Platelet activation leads to activation and propagation of the complement system.

Authors:  Ian Del Conde; Miguel A Crúz; Hui Zhang; José A López; Vahid Afshar-Kharghan
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

Review 8.  The interaction between the complement system and hemostatic factors.

Authors:  Selin Oncul; Vahid Afshar-Kharghan
Journal:  Curr Opin Hematol       Date:  2020-09       Impact factor: 3.218

Review 9.  Complement activation: an emerging player in the pathogenesis of cardiovascular disease.

Authors:  Angela M Carter
Journal:  Scientifica (Cairo)       Date:  2012-12-16

Review 10.  Complement in Hemolysis- and Thrombosis- Related Diseases.

Authors:  Shanshan Luo; Desheng Hu; Moran Wang; Peter F Zipfel; Yu Hu
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.